Bayer AG Sponsored ADR (BAYRY)
Bayer: U.S. Supreme Court could decide in June whether it will hear glyphosate case
Bayer said on Tuesday that the U.S. Supreme Court could decide as early as next month whether it will hear the German company's request to sharply limit litigation that could run into the billions of dollars over disputed claims that its Roundup weedkiller causes cancer.
Bayer posts smaller than expected 7.4% drop in quarterly adjusted profit
Bayer on Tuesday posted a slower decline in first-quarter adjusted earnings than the market had feared as strong prescription numbers for new drugs offset a drop in its soy and cotton seed business.
Bayer Confirms Guidance Despite Net Profit Drop
The company stuck to its full-year outlook on better-than-expected sales and adjusted earnings, but posted a fall in net profit.
Are Medical Stocks Lagging Bayer (BAYRY) This Year?
Here is how Bayer Aktiengesellschaft (BAYRY) and Boston Scientific (BSX) have performed compared to their sector so far this year.
Bayer to Slash Hundreds of Jobs in Crop Division Overhaul
The company said it will discontinue certain production activities at its Dormagen and Frankfurt am Main sites.
Farmers' Favorite Weedkiller Nears Its End, Bayer Warns
The German company cites mounting costs from lawsuits blaming Roundup for causing cancer.
Bayer Obtains Full FDA Approval for Oncology Drug Vitrakvi
The FDA converts its accelerated approval to full approval for BAYRY's oncology drug, Vitrakvi, on positive data from confirmatory studies.
Are Medical Stocks Lagging Bayer (BAYRY) This Year?
Here is how Bayer Aktiengesellschaft (BAYRY) and Lonza Group Ag (LZAGY) have performed compared to their sector so far this year.
Bayer renews bid for US Supreme Court to curb glyphosate cases
Bayer said on Friday it was again petitioning the U.S. Supreme Court to sharply limit legal claims that its Roundup weedkiller causes cancer, seeking to avoid potentially billions of dollars in damages.
Bayer's Vividion Initiates Dosing in Early-Stage Cancer Study
BAYRY subsidiary Vividion Therapeutics doses the first patient in a phase I study on VVD-159642 to treat advanced solid tumors.
Bayer eyes launch of menopause relief, heart drugs this year
Bayer said on Tuesday it was preparing market launches this year of two new drugs that could each have annual peak sales of at least $1 billion, as it seeks to strengthen its pharmaceuticals business amid a high debt burden.
Bayer Licenses PRMT5 inhibitor From Suzhou Puhe BioPharma
Bayer obtains an exclusive worldwide license for MTA-cooperative PRMT5 inhibitor from Suzhou Puhe BioPharma for selective targeting of MTAP-deleted tumors.
